{"url_path":"/sec/smti/8-k/2026-06-04/item-1-02","section_key":"item-1-02","section_title":"Item 1.02 Termination of a Material Definitive Agreement.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/714256/0001493152-26-027274-index.html","accession_number":"0001493152-26-027274","cik":"0000714256","ticker":"SMTI","issuer_name":"Sanara MedTech Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/714256/0001493152-26-027274-index.html","primary_entity_key":"0000714256","primary_entity_name":"Sanara MedTech Inc."},"word_count":313,"has_tables":true,"body_markdown":"**Item\n1.02 Termination of a Material Definitive Agreement.**\n\n \n\nAs\npreviously disclosed, on March 20, 2023, Sanara MedTech Inc. (the “Company”) entered into a Transaction Advisory Services\nAgreement (the “Services Agreement”) with The Catalyst Group, Inc., a Texas corporation (“Catalyst”), effective\nas of March 1, 2023. Pursuant to the Services Agreement, Catalyst agreed to perform certain transaction advisory, business and organizational\nstrategy, finance, marketing, operational and strategic planning, relationship access and corporate development services for the Company\nin connection with any merger, acquisition, recapitalization, divestiture, financing, refinancing, or other similar transaction in which\nthe Company may have been, or may have considered becoming, involved, and any such additional services as mutually agreed upon in writing\nby and between the Company and Catalyst. As previously disclosed, the Company’s Chairman, Ronald T. Nixon, is the founder\nand managing partner of Catalyst, and Catalyst and its affiliates collectively beneficially own more than 5% of the Company’s outstanding\ncommon stock.\n\n \n\nOn\nJune 2, 2026, in connection with the Company’s shift in strategy to focus on soft tissue repair and bone fusion products for the\nsurgical market, the Company entered into a Mutual Termination Agreement (the “Mutual Termination Agreement”) with Catalyst,\npursuant to which the parties agreed to terminate the Services Agreement, effective immediately. Pursuant to the Mutual Termination Agreement,\ncertain covenants contained in the Services Agreement, including those relating to indemnification and confidentiality, will remain in\nfull force and effect in accordance with the terms of the Services Agreement. The Company did not pay a fee or penalty in connection\nwith the termination of the Services Agreement.\n\n \n\n \n\n \n\n** **\n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\nDate:\nJune 4, 2026\n\n \n\n \n**Sanara\nMedTech Inc**.\n\n \n \n \n\n \nBy:\n*/s/\nElizabeth B. Taylor*\n\n \nName: \nElizabeth\nB. Taylor\n\n \nTitle:\nChief\nFinancial Officer"}